Needham Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)

In a report released today, Serge Belanger from Needham maintained a Buy rating on Pacira Pharmaceuticals (PCRXResearch Report), with a price target of $76.00. The company’s shares opened today at $54.54.

According to TipRanks, Belanger is a 4-star analyst with an average return of 3.2% and a 44.90% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Heron Therapeutics, and Liquidia Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pacira Pharmaceuticals with a $81.71 average price target, a 49.82% upside from current levels. In a report released today, Wedbush also reiterated a Buy rating on the stock with a $94.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $82.16 and a one-year low of $45.05. Currently, Pacira Pharmaceuticals has an average volume of 398.1K.

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PCRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Read More on PCRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed